Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Possibly Marketed Outside US

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Coccidiosis

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Preventing

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

EPA CompTox

2

FDA UNII

2

NCI_THESAURUS

2

PUBCHEM

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

ROXARSONE

H5GU9YQL7L

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

4-Hydroxy-3-nitrobenzenearsonic acid (commonly 3-Nitro, or its generic, Roxarsone) was a FDA approved for increased rate of weight gain, improved feed efficiency, and improved pigmentation for growing chickens and growing turkeys. For increased rate ...

of weight gain and improved feed efficiency for growing-finishing swine. Roxarsone is marketed as 3-Nitro by Zoetis, a former subsidiary of Pfizer now a publicly traded company. 3-Nitro is indicated for combination use with certain other medications as an effective aid in the prevention of coccidiosis, the most common infection in poultry. Roxarsone promotes angiogenesis in vivo, and a VEGF/VEGFR mechanism may be involved. In September 2013, the FDA announced that Zoetis and Fleming Laboratories would voluntarily withdraw current roxarsone, arsanilic acid, and carbarsone approvals, leaving only nitarsone approvals in place. In 2015 FDA withdraw the approval of using nitarsone in animal feeds. The ban will came into effect at the end of 2015. Roxarsone is banned in the European Union.

MONOSODIUM 3-NITRO-4-HYDROXYPHENYLARSONATE

0G63Q22980

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

4-Hydroxy-3-nitrobenzenearsonic acid (commonly 3-Nitro, or its generic, Roxarsone) was a FDA approved for increased rate of weight gain, improved feed efficiency, and improved pigmentation for growing chickens and growing turkeys. For increased rate ...

of weight gain and improved feed efficiency for growing-finishing swine. Roxarsone is marketed as 3-Nitro by Zoetis, a former subsidiary of Pfizer now a publicly traded company. 3-Nitro is indicated for combination use with certain other medications as an effective aid in the prevention of coccidiosis, the most common infection in poultry. Roxarsone promotes angiogenesis in vivo, and a VEGF/VEGFR mechanism may be involved. In September 2013, the FDA announced that Zoetis and Fleming Laboratories would voluntarily withdraw current roxarsone, arsanilic acid, and carbarsone approvals, leaving only nitarsone approvals in place. In 2015 FDA withdraw the approval of using nitarsone in animal feeds. The ban will came into effect at the end of 2015. Roxarsone is banned in the European Union.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1